Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, BioNTech SE's enterprise value is R$30,001 Mil.
BioNTech SE's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was R$-4,525 Mil. Therefore, BioNTech SE's EV-to-EBITDA for today is -6.63.
The historical rank and industry rank for BioNTech SE's EV-to-EBITDA or its related term are showing as below:
BSP:B1NT34'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -501.26 Med: 1.44 Max: 72.96
Current: -7.25
During the past 10 years, the highest EV-to-EBITDA of BioNTech SE was 72.96. The lowest was -501.26. And the median was 1.44.
BSP:B1NT34's EV-to-EBITDA is ranked worse than 100% of 409
companies
in the Biotechnology industry
Industry Median: 12.99
vs BSP:B1NT34: -7.25
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
BioNTech SE's PE Ratio (TTM) for today is calculated as:
BioNTech SE's share price for today is R$28.77.
BioNTech SE's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was R$-2.535.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for BioNTech SE's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BSP:B1NT34 vs INSM, INCY, MRNA: EV-to-EBITDA Comparison
For the Biotechnology subindustry, BioNTech SE's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioNTech SE EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioNTech SE's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where BioNTech SE's EV-to-EBITDA falls into.
BioNTech SE's current Enterprise Value is R$30,001 Mil.
BioNTech SE's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was R$-4,525 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioNTech SE (BSP:B1NT34) has a EV-to-EBITDA of -6.63 as of Aug. 07, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on BioNTech SE. According to the industry distribution chart, BioNTech SE ranks #999999 out of 409 companies in the Biotechnology industry.
Is BioNTech SE's EV-to-EBITDA too high?
BioNTech SE's current EV-to-EBITDA is -6.63. Based on the distribution chart, BioNTech SE ranks #999999 out of 409 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, BioNTech SE has a GF Score™ of 50/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does BioNTech SE's EV-to-EBITDA compare to INSM and INCY?
According to the Biotechnology industry distribution chart, BioNTech SE ranks #999999 out of 409 companies for EV-to-EBITDA. This places BioNTech SE in the lower half of its industry. The industry median EV-to-EBITDA is 12.99. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 12.99, based on 409 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on BioNTech SE. For the Biotechnology industry, the median EV-to-EBITDA is 12.99 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioNTech SE's current EV-to-EBITDA is -6.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioNTech SE stock overvalued right now?
Based on GuruFocus' analysis, BioNTech SE (BSP:B1NT34) is currently considered Fairly Valued. The stock's GF Value™ is R$28.14, compared to a current price of R$28.77 — trading 2.2% above its estimated fair value. The current EV-to-EBITDA is -6.63. BioNTech SE's overall GF Score™ is 50/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For BioNTech SE (BSP:B1NT34), the current EV-to-EBITDA is -6.63 as of Aug. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioNTech SE (BSP:B1NT34) Overvalued in 2026?
Based on GuruFocus' analysis, BioNTech SE stock appears to be overvalued.
The current stock price of R$28.77 is trading 2.2% above its estimated GF Value™ of R$28.14.
GuruFocus considers BioNTech SE to be Fairly Valued.
Key valuation signals for BSP:B1NT34:
EV-to-EBITDA: -6.63
GF Value™: R$28.14 vs. price of R$28.77 (2.2% above fair value)
No single metric tells the full story. See the BSP:B1NT34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens and neoantigens; monospecific and bispecific antibodies; and antibody-drug conjugates, or ADCs. Comirnaty, its Pfizer-partnered covid vaccine, is its first commercialized product.
50GF Score
Get the complete analysis for BSP:B1NT34
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:B1NT34 has been successfully added to your 
